Immuron (ASX: IMC)


Immuron (ASX: IMC) is a biopharmaceutical company developing and commercialising oral immunotherapeutics for the treatment of gut mediated diseases. www.immuron.com

Immuron ASX IMC NASDAQ IMRN SARS-CoV-2 COVID-19 antiviral studies Travelan Protectyn

Immuron’s commercially available products found to neutralise COVID-19 during in vitro research

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demons...
Immuron ASX IMC NASDAQ IMRN US DoD Naval Medical Research Center Phase 2 FDA Prevent Acute Infectious Diarrhea

Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli

Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis a...
Immuron ASX IMC North American Travelan sales increase

Immuron posts strong global sales growth for Travelan anti-diarrhoea product

Microbiome company Immuron (ASX: IMC) has posted a six-monthly unaudited gross revenue of $1.68 million for worldwide sales of its over-the-coun...
Immuron ASX IMC US Department of Defense funding Campylobacter

US Department of Defense to fund Immuron in combatting gastrointestinal infections

Microbiome company Immuron (ASX: IMC), a firm that specialises in developing oral immunotherapeutic treatments for gut mediated diseases, has st...
Immuron ASX IMC Travelan North America sales revenue 2019

Immuron’s Travelan anti-diarrhea product drives record revenue in North America

Immuron (ASX: IMC) revealed its full year 2019 revenue in North America has grown more than 50% to reach $1.16 million – driven by its Travelan ...
Immuron ASX IMC US Department of Defense Travelan Shigellosis challenge study Shigella

Immuron reports positive results from Travelan testing, develops anti-dysentery vaccine products

Australian biopharmaceutical company Immuron (ASX: IMC) has reported positive results from a study designed to test the efficacy of Travelan ant...
Immuron ASX IMC US Department of Defense gastro infections research Travelan

Immuron and US Department of Defense look to develop silver bullet for gastro infections

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral imm...
Immuron ASX IMC colitis IBD irritable bowel syndrome

Immuron takes aim at the rapid growth of autoimmune diseases

Biopharmaceutical company Immuron (ASX: IMC) has hailed its colitis preclinical program at the University of Zürich, Switzerland as a complete s...
Immuron ASX IMC Travelan sales

Immuron achieves strong sales numbers with Travelan

Microbiome biopharmaceutical company Immuron (ASX: IMC) has revealed encouraging sales numbers in relation to its over-the-counter gastrointesti...
Immuron ASX IMC positive clinical study results fatty liver disease

Immuron reports positive clinical study results in the fight against fatty liver disease

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis...
Immuron ASX IMC Travelan US Department of Defense

Immuron’s Travelan successful in US Department of Defense testing

Microbiome biopharmaceutical company Immuron (ASX: IMC) reported its commercially available Travelan had performed well during United States Dep...
Immuron IMC first stage colitis preclinical program

Immuron successfully completes first stage colitis preclinical program

Immuron Limited (ASX: IMC), has successfully completed the first stage of its colitis preclinical program at the University of Zurich, Switzerla...